- Cleveland BioLabs, Inc. CBLI shares tumbled 17.3 percent to $3.97 after surging 194.48 percent on Monday.
- Barracuda Networks Inc CUDA shares declined 16.3 percent to $19.60. Barracuda posted upbeat earnings for its fourth quarter.
- Adeptus Health Inc ADPT shares dropped 16.4 percent to $1.68.
- Arena Pharmaceuticals, Inc. ARNA shares tumbled 15.5 percent to $1.25. Arena Pharmaceuticals priced its 60 million share offering at $1.15 per share.
- Inpixon INPX shares dipped 14 percent to $2.84. Inpixon posted a Q4 GAAP net loss of $7.51 per share and disclosed that the FBI has renewed contract with Inpixon Federal.
- Wins Finance Holdings Inc WINS shares fell 12 percent to $60.00.
- Cardinal Health Inc CAH shares dropped 11.2 percent to $72.69. Cardinal Health announced plans to acquire patient portfolio from Medtronic for $6.1 billion. The company expects FY17adjusted earnings outlook at the bottom of its previous guidance range.
- OCI Partners LP OCIP fell 9.9 percent to $7.75. Citigroup downgraded OCI Partners from Neutral to Sell.
- AirMedia Group Inc (ADR) AMCN shares declined 9.5 percent to $2.81.
- Skypeople Fruit Juice Inc SPU shares dropped 7.9 percent to $2.57. SkyPeople Fruit Juice reported a FY16 net loss of $5.5 million on sales of $34.4 million.
- Goldman Sachs Group Inc GS shares declined 7.9 percent to $217.54 after the bank reported downbeat earnings for its first quarter.
- Kate Spade & Co KATE shares dropped 7.2 percent to $18.01. Kate Spade reported Q1 GAAP earnings of $0.01 per share on revenue of $271 million.
- Wi-Lan Inc (USA) WILN shares fell 6.1 percent to $1.87. WiLAN reported corporate developments and new growth strategy. The company also announced plans to buy International Road Dynamics for $3.17 per share in cash.
- Oncomed Pharmaceuticals Inc OMED shares dropped 4.2 percent to $3.84. Cantor Fitzgerald downgraded Oncomed Pharmaceuticals from Buy to Neutral.
- Harley-Davidson Inc HOG declined 3 percent to $57.59. Harley-Davidson posted upbeat quarterly earnings, but kept its guidance unchanged for 2017.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
